Simulated microgravity model of ovarian tumor growth

1993 ◽  
Author(s):  
Jeanne Becker ◽  
Thomas Goodwin ◽  
Tacey Prewett ◽  
Glenn Spaulding
Keyword(s):  
Tumor Growth ◽  
Ovarian Tumor ◽  
Simulated Microgravity

scholarly journals Ubiquitin E3 ligase MARCH7 promotes ovarian tumor growth

Oncotarget ◽  
2015 ◽  
Vol 6 (14) ◽  
pp. 12174-12187 ◽  
Author(s):  
Jianguo Hu ◽  
Ying Meng ◽  
Tinghe Yu ◽  
Lina Hu ◽  
Ming Mao
Keyword(s):  
Tumor Growth ◽  
Ovarian Tumor ◽  
E3 Ligase ◽  
Ubiquitin E3 Ligase

scholarly journals In vivo anti‐V‐ATPase antibody treatment delays ovarian tumor growth by increasing antitumor immune responses

2020 ◽  
Vol 14 (10) ◽  
pp. 2436-2454
Author(s):  
Arpita Kulshrestha ◽  
Gajendra K. Katara ◽  
Safaa A. Ibrahim ◽  
Valerie E. Riehl ◽  
Sylvia Schneiderman ◽  
...  
Keyword(s):  
Immune Responses ◽  
Tumor Growth ◽  
Ovarian Tumor ◽  
Antibody Treatment ◽  
Treatment Delays

Targeting septins controls ovarian tumor growth

2020 ◽  
Vol 159 ◽  
pp. 142-143
Author(s):  
R. Singh ◽  
N. Khazan ◽  
R. Turner ◽  
M.N. Towner ◽  
K. Kim ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Ovarian Tumor

scholarly journals Cyclin D1 Expression and the Inhibitory Effect of Celecoxib on Ovarian Tumor Growth in Vivo

2010 ◽  
Vol 11 (10) ◽  
pp. 3999-4013 ◽  
Author(s):  
Wei Li ◽  
Hong-Ru Jiang ◽  
Xiao-Li Xu ◽  
Jie Wang ◽  
Jun Zhang ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Cyclin D1 ◽  
Ovarian Tumor ◽  
Inhibitory Effect

Abstract 3579: Long non-coding RNA ADAMTS9-AS2 inhibits ovarian tumor growth via Annexin A1

2019 ◽  
Author(s):  
Cristian Rodriguez-Aguayo ◽  
Emine Bayraktar ◽  
Lingegowda S. Mangala ◽  
Cristina Ivan ◽  
Gabriel Lopez-Berestein ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Ovarian Tumor ◽  
Annexin A1 ◽  
Non Coding Rna ◽  
Long Non Coding Rna

scholarly journals Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis

2009 ◽  
Vol 106 (9) ◽  
pp. 3426-3430 ◽  
Author(s):  
Y.-H. Huang ◽  
Y. Bao ◽  
W. Peng ◽  
M. Goldberg ◽  
K. Love ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Gene Silencing ◽  
Ovarian Tumor ◽  
Tumor Growth And Metastasis

scholarly journals Autoimmune mediated regulation of ovarian tumor growth

2012 ◽  
Vol 124 (1) ◽  
pp. 98-104 ◽  
Author(s):  
Cengiz Z. Altuntas ◽  
Ritika Jaini ◽  
Pavani Kesaraju ◽  
Daniel Jane-wit ◽  
Justin M. Johnson ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Ovarian Tumor

Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice

2015 ◽  
Vol 309 (1) ◽  
pp. F35-F47 ◽  
Author(s):  
Malvika H. Solanki ◽  
Prodyot K. Chatterjee ◽  
Xiangying Xue ◽  
Madhu Gupta ◽  
Ivy Rosales ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Tumor Growth ◽  
Mrna Expression ◽  
Ovarian Tumor ◽  
Magnesium Deficiency ◽  
Kidney Injury ◽  
Tumor Bearing ◽  
Magnesium Status

Cisplatin, a commonly used chemotherapeutic for ovarian and other cancers, leads to hypomagnesemia in most patients and causes acute kidney injury (AKI) in 25–30% of patients. Previously, we showed that magnesium deficiency worsens cisplatin-induced AKI and magnesium replacement during cisplatin treatment protects against cisplatin-mediated AKI in non-tumor-bearing mice (Solanki MH, Chatterjee PK, Gupta M, Xue X, Plagov A, Metz MH, Mintz R, Singhal PC, Metz CN. Am J Physiol Renal Physiol 307: F369–F384, 2014). This study investigates the role of magnesium in cisplatin-induced AKI using a human ovarian tumor (A2780) xenograft model in mice and the effect of magnesium status on tumor growth and the chemotherapeutic efficacy of cisplatin in vivo. Tumor progression was unaffected by magnesium status in saline-treated mice. Cisplatin treatment reduced tumor growth in all mice, irrespective of magnesium status. In fact, cisplatin-treated magnesium-supplemented mice had reduced tumor growth after 3 wk compared with cisplatin-treated controls. While magnesium status did not interfere with tumor killing by cisplatin, it significantly affected renal function following cisplatin. Cisplatin-induced AKI was enhanced by magnesium deficiency, as evidenced by increased blood urea nitrogen, creatinine, and other markers of renal damage. This was accompanied by reduced renal mRNA expression of the cisplatin efflux transporter Abcc6. These effects were significantly reversed by magnesium replacement. On the contrary, magnesium status did not affect the mRNA expression of cisplatin uptake or efflux transporters by the tumors in vivo. Finally, magnesium deficiency enhanced platinum accumulation in the kidneys and renal epithelial cells, but not in the A2780 tumor cells. These findings demonstrate the renoprotective role of magnesium during cisplatin AKI, without compromising the chemotherapeutic efficacy of cisplatin in an ovarian tumor-bearing mouse model.

Sign in / Sign up

Export Citation Format

Share Document